← All trials
NCT00685698
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2008
- Primary completion
- Apr 1, 2009
- Completion date
- Jun 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- TaiGen Biotechnology Co., Ltd.Lead sponsor
- HealthCare Partners, Pasadena, USAOverall official - principal investigator
- The Amputation Prevention Center at Broadlawns Medical Center, Des Moines, USAOverall official - principal investigator
- HealthCare Partners, Montebello, USAOverall official - principal investigator
- Montana Hospital, Pretoria, South AfricaOverall official - principal investigator
- Eastmed Academic Clinical Trial Center, East Lynne, South AfricaOverall official - principal investigator
- Park Medical Center, Witbank, South AfricaOverall official - principal investigator
- Chang Gung UniversityOverall official - principal investigator
- Cheng-Gung Memorial HospitalOverall official - principal investigator
- Taipei Medical UniversityOverall official - principal investigator
- TaiGen Biotechnology Co., Ltd.Overall official - principal investigator
- Government of TaiwanStudy chair
- Cardinal Tien HospitalOverall official - principal investigator
- ChengChing HospitalOverall official - principal investigator
- Chimei Medical CenterOverall official - principal investigator
- KhonKaen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.